Comparative Pharmacology
Head-to-head clinical analysis: AUSTEDO versus INGREZZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUSTEDO versus INGREZZA.
AUSTEDO vs INGREZZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deuterated tetrabenazine; inhibits vesicular monoamine transporter 2 (VMAT2), reducing dopamine uptake into synaptic vesicles and leading to decreased presynaptic dopamine release, similar to tetrabenazine but with altered pharmacokinetics due to deuterium substitution.
Vesicular monoamine transporter 2 (VMAT2) inhibitor; reduces presynaptic dopamine release.
Initial 6 mg orally once daily; titrate by 6 mg increments at weekly intervals to a maximum of 48 mg/day. For tolerability, may divide into twice daily dosing (e.g., 12 mg twice daily).
80 mg orally once daily; may titrate from 40 mg once daily for 7 days to reduce nausea.
None Documented
None Documented
5-9 hours (parent); 7-10 hours (active metabolite). Steady state within 2-3 days.
Terminal elimination half-life of deutetrabenazine is 9-10 hours; clinical context: supports twice-daily dosing.
Urine (75-85% as metabolites, <5% unchanged); feces (10-15%)
Approximately 60% renal (as unchanged drug and metabolites) and 30% fecal.
Category C
Category C
VMAT2 Inhibitor
VMAT2 Inhibitor